drugset / Trial / NCT02955147
Ustekinumab for the Treatment of Giant Cell Arteritis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether ustekinumab is effective in the treatment of Giant Cell Arteritis (GCA)
Timeline
- Start
- 2016-12-01
- Primary completion
- 2019-07-25
- Completion
- 2019-09-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ustekinumab | Monoclonal antibody | 90 mg | — |
| Background | Prednisone | Other / unclassified | 20 mg | — |
| Background | Prednisone | Other / unclassified | 40 mg | — |
| Background | Prednisone | Other / unclassified | 60 mg | — |